F. Hoffmann-La Roche Ltd: Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma

• Short duration infusion of Gazyvaro (obinutuzumab)is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours
• Results from the phase IV GAZELLE study showed no new safety signals with the shorter infusion of Gazyvaro
• Shorter infusions could be more convenient for patients by reducing time in hospital and easing pressure on healthcare systems^[1]
  

Basel, 14 October 2021 - Roche] is an open-label, international, multicentre, single arm, phase IV study investigating the safety and efficacy of the short duration infusion

Dr. Nicolas Dunant Phone: [phone]	Patrick Barth Phone: [phone]
Dr. Barbara von Schnurbein Phone: [phone]	Karsten Kleine Phone: [phone]
Nina Mählitz Phone: [phone]	Nathalie Meetz Phone: [phone]
Sileia Urech Phone: [phone]

Roche Investor Relations
Dr. Karl Mahler Phone: [phone] e-mail: [e-mail] (mailto:[e-mail])	Jon Kaspar Bayard Phone: [phone] e-mail: [e-mail] (mailto:[e-mail])
Dr. Sabine Borngräber Phone: [phone] e-mail: [e-mail] (mailto:[e-mail])	Dr. Bruno Eschli Phone: [phone] e-mail: [e-mail] (mailto:[e-mail])
Dr. Birgit Masjost Phone: [phone] e-mail: [e-mail] (mailto:[e-mail])	Dr. Gerard Tobin Phone: [phone] e-mail: [e-mail] (mailto:[e-mail])
Investor Relations North America
Loren Kalm Phone: [phone] e-mail: [e-mail] (mailto:[e-mail])

Attachment

• 14102021_MR_Gazyva (https://ml-eu.globenewswire.com/Resource/Download/cc8f6d6e-4200-451c-96fc-26ad6df6c9c3)